A study pertaining to discovering metabolomics signatures in NSCLC patients undergoing anti-PD-1/PD-L1 therapy is underway at the Grenoble Alpes University Hospital in France and hopefully will be able to give more insight in the future about specific dietary compounds in the gut microbiome that can be linked to better treatment response [90]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.